Allergy Therapeutics PLC added Scott Leinenweber as a nonexecutive director, succeeding Jeff Barton, who retired from the board.
Barton joined the company's board in February 2017.
Leinenweber was nominated by Abbott Laboratories where he currently serves as vice president of investor relations and licensing & acquisitions. Abbott Laboratories owned 16.21% of the company as of Aug. 1, according to S&P Global Market Intelligence data.
U.K.-based Allergy Therapeutics is a biotechnology company focused on the treatment and diagnosis of allergic disorders.
